Verve Therapeutics
About Us
Why Heart Disease
Approach
Pipeline
Culture & Careers
News
Verve raises another $63m to develop gene-editing treatment for heart disease
Post navigation
Previous Post
Previous
10-year-old’s cholesterol was over 800. Can CRISPR fix the problem?
Next Post
Next
Verve Therapeutics Adds $63M to Edit Heart Attack Risk Out of Genes
Home
About Us
Why Heart Disease
Approach
Pipeline
Culture & Careers
News
Contact Us